ERBB2 and breast cancer: CircRNAs displayed a role also in drug-response, after treatment with Pertuzumab, which down-modulated the expression of a circRNA coding for a novel protein in BC triple-negative phenotypes [8], or in the case of Trastuzumab in HER2+ cells [9].